Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 21, Issue 11, 2006, Pages 3189-3195

  Davison, Sara N ^a,b   Jhangri, Gian S ^a   Johnson, Jeffrey A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE   (Canada)

Author keywords

Haemodialysis; Health related quality of life; Pain, symptom assessment; Symptom burden

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; EDMONTON SYMPTOM ASSESSMENT SYSTEM; FEMALE; HEALTH STATUS; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SELF CONCEPT; SEVERITY OF ILLNESS INDEX;

EID: 33749998975     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl380     Document Type: Article

References (38)

1. DeOreo PB. The use of patient-based instruments to measure, manage, and improve quality of care in dialysis facilities. Adv Ren Replace Ther 2001; 8: 125-130
2. Ifudu O, Paul HR, Homel P, Friedman EA. Predictive value of functional status for mortality in patients on maintenance hemodialysis. Am J Nephrol 1998; 18: 109-116
3. Mapes DL, Bragg-Gresham JL, Bommer J et al. Health-related quality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 54-60
4. McClellan WM, Anson CA, Birkeli K, Tuttle E. Functional status and quality of life: Predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol 1991; 44: 83-89
5. Fainsinger R, Davison SN, Brenneis C. A supportive care model for dialysis patients. Palliat Med 2003; 17: 81-82
6. Weisbord SD, Fried LF, Arnold RM et al. Prevalence, severity and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 2005; 16: 2487-2494
7. Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality of life across renal replacement therapies: A meta-analytic comparison. Am J Kidney Dis 2000; 35: 629-637
8. Davison SN, Jhangri GS. The impact of chronic pain on depression, sleep and the desire to withdraw from dialysis in hemodialysis patients. J Pain Symptom Manage 2005; 30: 465-473
9. Davison SN, Jhangri GS, Johnson JA. Cross sectional validity of a modified Edmonton Symptom Assessment System (ESAS) in dialysis patients: a simple method for the assessment of symptom burden. Kidney Int 2006; 69: 1621-1625
10. Kimmel PL, Peterson RA, Weihs KL et al. Aspects of quality of life in hemodialysis patients. J Am Soc Nephrol 1995; 6: 1418-1426
11. Kimmel PL, Emont SL, Newmann JM, Danko H, Moss AH. ESRD patient quality of life: Symptoms, spiritual beliefs, psychosocial factors, and ethnicity. Am J Kidney Dis 2003; 42: 713-721
12. Patel SS, Shah VS, Peterson RA, Kimmel PL. Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis. Am J Kidney Dis 2002; 40: 1013-1022
13. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis 2001; 38: 443-464
14. Hays RD. RAND-36 Health Status Inventory, Harcourt Brace & Company, San Antonio, Texas, 1998
15. Hays RD, Kallich JD, Mapes DL et al. Kidney Disease Quality of Life Short Form (KDQOL-SF), Version 1.3: A manual for use and scoring. RAND. 1-39. 1997. Santa Monica, CA, RAND
16. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton symptom assessment scale. Cancer 2000; 88: 2164-2171
17. Ware JE, Kosinski M, Keller SD. A 12-time short form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-233
18. Birbeck GI, Kim S, Hays RD, Vickery BG. Quality of life measures in epilepsy: How well can they detect change over time? Neurology 2000; 54: 1822-1827
19. Johnson JA, Maddigan SL. Performance of the RAND-12 and SF-12 summary score in type 2 diabetes. Qual Life Res 2004; 13: 449-456
20. Nordvedt MW, Riise T, Mohr KM, Nyland HI. Perfromances of the SF-36, SF-12 and RAND-36 summary scales in a multiple sclerosis population. Med Care 2000; 38: 1022-1028
21. Taft C, Karlsson J, Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores? Qual Life Res 2001; 10: 395-404
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383
23. Van Manen JG, Korevaar JC, Dekker FW et al. Adjustment for comorbidity in studies on health status in ESRD patients: Which comorbidity index to use? J Am Soc Nephrol 2003; 14: 478-485
24. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML. A simple comorbity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 2000; 108: 609-613
25. K/DOQI Guidelines: Part 6, Guideline 12: Association of level of GFR with indices of functioning and well-being. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002; 39: S112
26. Meyers K, Benz R, and HEMO Study Group. Quality of life outcomes in the HEMO study. J Am Soc Nephrol 2002; 13: 421A-422A
27. Barrett BJ, Vavasour HM, Major A, Parfrey PS. Clinical and psychological correlates of somatic symptoms in patients on dialysis. Nephron 1990; 55: 10-15
28. Blake PG, Sombolos K, Abraham G et al. Lack of correlation between urea kinetic indices and clinical outcomes in CAPD patients. Kidney Int 1991; 39: 700-706
29. Davison SN. Chronic pain in end-stage renal disease. Adv Chronic Kidney Dis 2005; 12: 326-334
30. Evans RW, Radar B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. J Am Med Assoc 1990; 263: 825-830
31. Beusterien KM, Nissenson AR, Port FK et al. The effects of recombinant human erythropoietin of functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773
32. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989; 14: 14-18
33. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000
34. Moreno F, Aracil FJ, Perez R, Valderrabano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996; 27: 538-556
35. Muirhead N. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990; 300: 573-578
36. Revicki DA, Brown RE, Feeny DH et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548-554
37. Canadian Organ Replacement Register. Dialysis and Renal Transplantation. Canadian Organ Replacement Register. 2001 Report. 2002. Ottawa, Ontario, Canadian Institute for Health Information
38. U.S. Renal Data System, National Institutes of Health, and National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Renal Data System. USRDS 2005. 2005 Annual Report: Atlas of End-Stage Renal Disease in the United States. 2005. Bethesda, MD USA